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ABSTRACT
EVALUATING SOLUBLE AXL AS A BIOMARKER FOR GLIOBLASTOMA
By
Daniel Raymond

AXL, a receptor tyrosine kinase, is known to promote malignant phenotypes in various
types of cancer. AXL overexpression is commonly observed in glioblastoma and correlates with a
worse prognosis. Detectable in most biological fluids, the extracellular domain of AXL, sAXL, is
the product of enzymatic cleavage by ADAM10/17. Here we used ELISA, BCA and BCG assays
to characterize blood serum from 23 newly diagnosed GBM patients which was collected roughly
24 hours before and after surgery as well as every three months post-surgery, corresponding to
follow-up treatment visits. Immunoblotting was used to determine relative AXL expression in 13
patient tumor tissue samples. Additionally, T-1 weighted MRI scans were used to interpolate preoperative tumor volume in all participating patients. Here we report that sAXL was elevated in the
84 GBM samples compared to the 40 control samples (p = 0.013). Normalizing sAXL values
against corresponding serum albumin concentrations further defined the distinction between the
two groups (p < 0.0001). While in the 19 paired, pre- and post- operative samples, sAXL did not
respond significantly to surgical intervention, normalizing the values against albumin showed a
significant elevation in response to surgery (p = 0.013). In patients whose pre-operative samples
presented with sAXL elevated compared to the healthy control average (30.16 ng/mL), there was a
strong positive correlation between sAXL and AXL found in the corresponding tumor tissue.
Though sAXL shed from brain tumors is detectable in the serum of GBM patients, in this small
series of patients, it does not correlate with tumor volume.

i

Copyright by
Daniel Raymond
2020

2

ACKNOWLEDGMENTS

This project was made possible due to the collaborative support of the Upper Michigan
Brain Tumor Center, the Aurora Research Institute, Excellence in Education Grant and
graduate research assistantship. I would like to extend my sincerest gratitude to my thesis
committee members Dr. Robert Winn, Dr. Richard Rovin, and Dr. Amber Lacrosse for
their guidance and support. Additionally, I would like to thank Dr. Parvez Akhtar, Joseph
Duffy, Sam Zwernik, Beau Adams, Casey Juntila, John Paul Velasco, and all of the
volunteer blood donors from Northern Michigan University.

ii

This work is dedicated in memory of Bill McBrayer and Ryan Kuzmak

iii

TABLE OF CONTENTS
Abstract ............................................................................................................................... 1
Acknowledgments............................................................................................................... ii
List of Figures .................................................................................................................... vi
List of Abbreviations ....................................................................................................... viii
Introduction ......................................................................................................................... 1
Aims and Goals ................................................................................................................. 11
Methods and Materials ...................................................................................................... 12
Obtaining Blood Serum Samples ..................................................................................12
Dilution Scheme for Serum Samples ............................................................................13
Preparation of Human AXL ELISA Kit........................................................................16
Enzyme-linked Immunosorbent Assay .........................................................................17
Optimizing the AXL ELISA for Ideal Interassay Variation .........................................18
Bicinchoninic Acid (BCA) Assay to Determine Total Serum Protein .........................20
Bromocresol Green (BCG) Assay to Determine Total blood albumin .........................20
Tissue Sonication ..........................................................................................................21
Western Blotting ...........................................................................................................21
Pre-Operative MRI analysis ..........................................................................................23
Data Analysis ................................................................................................................23
Results ............................................................................................................................... 24
Characterizing sAXL in GBM and Healthy Control Populations.................................24
Using sAXL as a Predictive Biomarker for GBM Presence ......................................36
Serum sAXL in Response to Surgical Intervention ......................................................40
Serum sAXL in Response to Treatment........................................................................44
Associations between sAXL, AXL and Tumor Volume ..............................................47
Discussion ......................................................................................................................... 55
Conclusions ....................................................................................................................... 62
References ......................................................................................................................... 63
iv

Appendix A ....................................................................................................................... 75
NMU IRB Approval letter for the colloection of Blood Serum ...................................75
Appendix B ....................................................................................................................... 77
Aurora IRB Approval letter for the colloection of Blood Serum ................................77

v

LIST OF FIGURES
Figure 1: AXL Signaling Pathway Overview ..................................................................... 9
Figure 2: Regulating RTK Signaling Through Sheddase Activity ................................... 10
Figure 3: Serum Dilution Scheme..................................................................................... 15
Figure 4: Protein Stability Test: ELISA............................................................................ 25
Figure 5: Protein Stability Test: BCA assay ..................................................................... 26
Figure 6: ELISA Inter-assay Variation: Individual Protein Standards ............................. 27
Figure 7: ELISA Inter-assay Variation: Batch-Prepared Protein Standards ..................... 28
Figure 8: sAXL in GBM and Healthy Blood Serum ........................................................ 30
Figure 9: Serum Albumin in GBM and Healthy Blood Serum ........................................ 31
Figure 10: Total Protein in GBM and Healthy Blood Serum ........................................... 32
Figure 11: sAXL/Albumin Ratio in GBM and Healthy Blood Serum ............................. 33
Figure 12: sAXL/Total Protein Ratio in GBM and Healthy Blood Serum....................... 34
Figure 13: Serum sAXL Concentration in Males and Females Separated by GBM Status
........................................................................................................................................... 35
Figure 14: sAXL Concentrations: Control, Pre-operative and Post-operative samples ... 37
Figure 15: Serum Albumin Concentration: Control, Pre-operative and Post-operative
samples .............................................................................................................................. 38
Figure 16: sAXL Normalized by Albumin: Control, Pre-operative and Post-operative
samples .............................................................................................................................. 39
Figure 17: Change in Serum sAXL: Pre-Post Surgery ..................................................... 41
Figure 18: Change in Normalized Serum sAXL: Pre-Post Surgery ................................. 42
Figure 19: Pre-opertaive Tumor Volume vs. Change in sAXL ....................................... 43
vi

Figure 20 : sAXL at Each Treatment Timepoint and Post-operative Samples ................. 45
Figure 21: sAXL Normalized by Albumin at Each Timepoint and Postoperative Samples
........................................................................................................................................... 46
Figure 22: Membrane sAXL Expression in GBM Tumor Lysates ................................... 50
Figure 23: T1 Weighted MRI Scan of GBM Tumor ........................................................ 51
Figure 24: Pre-operative sAXL is Associated with Membrane AXL ............................... 54

vii

LIST OF ABBREVIATIONS

GBM - Glioblastoma Multiforme
CT - Computed Tomography
MRI - Magnetic Resonance Imaging
RTK - Receptor Tyrosine Kinase
SH2 - Src Homology 2
TAM - Tyro3/AXL/Mer
Gas6 - Growth-Arrest Specific Factor 6
PtdSer - Phosphatidylserine
VSMC - Vascular Smooth Muscle Cells
MAPK - Mitogen Activated Protein Kinase
ERK - Extracellular Signal-Regulated Kinase
MEK - MAPK/ERK Kinase
MMP9 - Matrix Metalloproteinase 9
VEGFR - Vascular Epidermal Growth Factor Receptor
NF-κB - Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B cells
PI3K - Phosphoinositide 3-Kinase
Akt - RAC-Alpha Serine/Threonine-Protein Kinase
TLR - Toll-Like Receptor
IFNAR - Interferon-α/β Receptor
BCL2 - B-Cell Lymphoma 2 Encoded Protein
viii

EMT - Epithelial-to-Mesenchymal Transition
NSCLC - Non-Small Cell Lung Cancer
mRNA - Messenger Ribonucleic Acid
RNA - Ribonucleic Acid
DNA - Deoxyribonucleic Acid
IHC - Immunohistochemistry
MZF1 - Myeloid Zinc Finger 1
STAT1 - Signal Transducer and Activator of Transcription 1
HIF1α - Hypoxia-Inducible Factor 1- Alpha
AP1 - Activator Protein 1
CpG - 5'-C-phosphate-G-3'
miRNA - Micro Ribonucleic Acid
ADAM10/17 - A Disintegrin and Metalloproteinase 10/17
kDa - Kilodalton
EGFR - Epidermal Growth Factor Receptor
ECM - Extracellular Matrix
HER2/4 - Human Epidermal Growth Factor Receptor 2/4
TIMP1 - Tissue Inhibitor of Metalloproteinases
CLS - Clinical Laboratory Sciences
IRB - Institutional Review Board
rpm - Revolutions per Minute
LCB - LowCross™ Buffer
PBS - Phosphate Buffered Saline
ix

ELISA - Enzyme-Linked Immunosorbant Assay
BCA - Bicinchoninic Acid
BCG - Bromocresol Green
BSA - Bovine Serum Albumin
HRP - Horseradish Peroxidase
BSRC – Biorepository and Specimens Resource Center
ARI - Aurora Research Institution
RIPA Buffer - Radioimmunoprecipitation Assay Buffer
NFDM - Non-Fat Dry Milk
PVDF - Polyvinylidene Difluoride
TBS - Tris-Buffered Saline
TBST - Tris-Buffered Saline+ Tween®20
ANOVA - Analysis of Variance
SEM - Standard Error of the Mean

x

INTRODUCTION

Based on the 2016 World Health Organization’s Classification System of Tumors
of the Central Nervous System, Glioblastoma Multiforme (GBM) is categorized as a
grade IV diffuse glioma due to its origin in glial progenitor cells and diffuse growth
pattern 1. Glioblastoma is the most aggressive form of malignant primary brain cancer
and affects about 3 individuals out of 100,000 each year in the United States alone 2.
Patients symptoms present quickly and can include headaches, abnormal physical
weakness and neurological abnormalities such as memory loss, confusion, blurred vision
or speech and loss of consciousness 3. Identification and subsequent diagnosis of the
disease is first determined by imaging techniques like CT or MRI scans followed by a
craniotomy to obtain a sample for molecular diagnostic testing 3. Standard treatment
involves maximal tumor resection followed by radiation and adjuvant chemotherapy 4.
Untreated, median survival time is only about 3 months2. Even with standard treatment,
median survival for GBM patients is about 15 months 5. GBM patient survival is
dependent on many factors including, but not limited to, age at diagnosis, sex, tumor
location and treatment type 6. However variable that may be, overall survival of GBM
patients 5 years after diagnosis is less than 5% 7. Because of the difficulties associated
with treating this disease, it is of the utmost importance to develop techniques that would
aid in the detection of GBM and monitor treatment progress.
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Cancer cells, in part, are distinct from normal cells in the composition of surface
proteins that reside on the cell membrane 8. Tyrosine kinases represent a minority of the
protein-coding portion of our genome but have played a dominate role in cancer research
since the discovery of the first proto-oncogene, src. Mutations that lead to constitutively
active forms of these signaling molecules can lead to cellular transformation. In fact,
deregulated signaling mechanisms are a defining characteristic of all neoplastic growths9.
This is represented in a central dogma of cancer research that malignant growths arise
from the accumulation of mutations in both an oncogene and a tumor suppressor gene.
These mutated genes or the product of their expression are frequent points of interest in
the study and treatment of cancer.
One way these tyrosine kinases can be separated into categories is based on the
location in which they function, the plasma membrane or the cytoplasm10. Receptor
tyrosine kinases (RTK) are found embedded in the plasma membrane and largely
function as the primary point of contact for environmental stimuli. These proteins
translate the signal from the extracellular environment through a process of enzymatic
reactions to the intracellular environment. Tyrosine kinases found in the cytoplasm
function as a cascade of mediators that typically transfer the signal from the membrane to
a vast range of targets within the cell, resulting in a response to the original stimuli. These
responses can range from translocation of transcription factors into the nucleus, in turn
modulating gene expression11, to the activation of cell proliferation or apoptotic
mechanisms12.
The process of RTK activation is initiated by the binding of a ligand to a pair of
its receptor proteins, often simultaneously13, resulting in activation of the dimer complex.
2

On the cytoplasmic side of this complex, the act of dimerization facilitates
autophosphorylation and then transphosphorylation of tyrosine residues on its subunits
that attract docking proteins containing SH2 domains. Cytoplasmic kinases interact with
this docking complex and pass the signal further downstream to ultimately affect some
kind of cellular response14. While point mutations causing constitutively active kinases
are one common cause of aberrant molecular signaling, simple overexpression of normal
RTK’s is another15.
One such case is that of receptor tyrosine kinase AXL (Ufo, Ark), a member of
the TAM kinase family along with Tyro3 (Sky) and Mer, and serve as key players in
numerous normal and malignant cellular functions. In 1988, the gene that codes for AXL
was first characterized as a novel proto-oncogene in human myeloid leukemia cells16.
Canonical activation of the AXL receptor dimer complex involves the binding of its
natural ligand, Growth-arrest specific factor 6 (Gas6), as well as interacting with the
phospholipid, phosphatidylserine (PtdSer)17–19. However, studies have suggested that in
the cases in which AXL is overexpressed, heterotypic activation20 and even ligandindependent receptor activation can occur21. When expressed normally and often in
concert with the other members of the TAM family, activation of AXL promotes various
normal cellular behaviors seen across different cell types. These include apoptotic cell
clearance22,23, dampening of cytokine induced inflammation 11,24, migration and survival
of certain types of neurons25–27 and Vascular Smooth Muscle Cells (VSMC) cells28–30,
differentiation and maturation of NK cells31, normal platelet aggregation32,33 and
spermatogenesis34.
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Whereas standard expression and activation of AXL leads to normal cellular
functions, overexpression has been shown to cause aberrant signaling that results in
malignant phenotypes (Figure 1) 35,36. Described below, these phenotypes include
increased survival, proliferation, migration, invasion, angiogenesis, immune suppression
and decreased sensitivity to chemotherapeutic intervention. AXL signaling has been
shown to stimulate cellular proliferation and protect from apoptosis through the
MEK/ERK35 and PI3K/Akt/NF-κB37,38 pathways. Invasion and migration are controlled
through pathways like Rac/p38 MAPK and ERK/MMP9 respectively. Angiogenesis has
been connected to AXL through in vivo studies demonstrating cross-talk between AXL
and VEGFR-2 activated Src family kinases (SFK), leading to downstream activation of
the PI3K/Akt pathway39. Immune suppression, primarily in the form of dampening the
responses of the immune system caused by cytokine release and TLR activation, is
facilitated by AXL negative regulation of the TLR and cytokine-associated receptors (eg.
IFNAR)24,11,37. Decreased drug sensitivity is a result of AXL-related mechanisms, one of
which involves upregulation of signaling proteins and transcription factors such as BCL2 and Twist40. Furthermore, the upregulation of various AXL-related pathways result in
epithelial to mesenchymal transition (EMT) in various cell types41–43.
Studies have been undertaken to understand the implications of aberrant AXL
signaling for patients with different cancers. In short and as summarized by Rankin and
Giaccia44, AXL plays a significant role in the phenotypic expression of different cancer
cells and is therefore a valuable therapeutic target. High AXL expression has been
correlated with worse survival rates in at least 14 types of cancer, including GBM45–59.
Additionally, AXL expression has been shown to confer drug resistance to cells in at
4

least five types of cancer40,59–64. Furthermore, AXL has been demonstrated to be an
important conduit to the molecular rewiring necessary for EMT and/or the maintenance
of this state in GBM65, breast cancer41–43, ovarian cancer66, NSCLC67 and pancreatic
cancer68. Taken together, these studies have demonstrated the significant role that
aberrant AXL signaling may play in numerous cancers and has bolstered efforts to target
AXL when treating these diseases.
Due to the similar effects of AXL overexpression and activation across a variety
of cancer subtypes, increased focus has been placed on using AXL-targeted drug therapy.
Various AXL inhibitors are at different stages of development with promising preclinical results69,70 suggesting that in specific cancers, these drugs can significantly
supplement the effectiveness of current treatments. Use of AXL-targeting smallmolecule inhibitors such as, Bemcentinib (BGB324; previously R428), and others are
currently at different phases of clinical trials in patients with GBM71 (NCT03965494),
pancreatic cancer72 (NCT03649321), NSCLC73,74 (NCT02922777, NCT02424617) and
AML/MDS75 (NCT02488408). However, despite the advanced stage of some of these
clinical trials, the long term efficacy of AXL targeting has not been reported. Although
these clinical efforts oriented towards treatment strategies are valuable, identification of
the disease at its earliest stages would drastically change the outcomes for the majority of
patients.
Specifically in GBM, AXL and Gas6 have been reported to be moderate to highly
expressed at both the mRNA and protein level in in the majority of cases. Similarly, in
patient tissue samples with high AXL levels, determined by IHC, AXL and Gas6
expression were correlated with shorter time to disease progression and was associated
5

with a poor survival rate. Furthermore, AXL protein expression was only found to be
present in glioma tumor tissue and its vasculature, but absent in non-neoplastic tissues45.
Another study reported that AXL was elevated in GBM and was correlated with a worse
prognosis and showed that AXL overexpression directly correlated with drug resistance
and contributed to tumorigenesis59. There are numerous studies reporting significant
expression of AXL in various regions of the brain, however, a comprehensive study
performed in 2015 resulting in the Human Protein Atlas, indicates that of all the organs
where AXL protein expression is found, it is least abundant in the brain76. These studies
highlight the role AXL plays in GBM, from its origin through the treatment and outcome
of the patient.
Cellular regulation of AXL can be found at all levels of expression, from
transcriptional controls to post-translational deactivation through enzymatic cleavage.
Environmental stimuli trigger the cell to release transcription factors, several of which
have been demonstrated to act upon the axl gene. Several transcription factors like
MZF177, STAT111, HIF1α78 and AP179 have been shown to induce axl transcription.
However, methylation of CpG islands adjacent to the transcription factor binding sites
have been demonstrated to play an antagonistic role in the generation of axl mRNA80.
Once transcribed, axl mRNA does not always result in translation. In fact, despite
relatively equivalent expression of axl mRNA in different cell types, protein level AXL
expression is significantly different between cell types76,81. Post-transcriptional regulation
can take the form of ribosomal blockades by miRNAs such as miR-199a/b82 and miR34a82,83, preventing the translation of the AXL mRNA. Even after translation, the AXL
protein can also be subject to ubiquitination and subsequent degradation84. Another post6

translational means of protein regulation is modification by ADAM proteins that have
been shown to regulate AXL activity by enzymatically cleaving the extracellular
domain21,85. The regulatory process for protein creation and function is a complex and
finely tuned system that nevertheless offers various points to target for detection or
treatment of AXL-influenced diseases.
This soluble form of AXL, denoted sAXL, is nearly ubiquitous in the body since
it is a product of membrane AXL, whose expression is nearly ubiquitous on some level.
This is also partially due to the small size of sAXL (43 kDa) making it capable of
permeating certain blood vessels86. Presumably due to a lack in uniformity of testing,
there is a range of reported sAXL concentrations in blood serum from healthy control
populations. Regardless, sAXL can be found in the majority of the relevant biological
fluids such as blood serum87 or plasma88,89, cerebrospinal fluid90, urine91 and peritoneal
effusions92. Evidence supporting the existence of a soluble AXL extracellular domain
(sAXL) generated due to proteolytic cleavage, as opposed to alternative transcript
splicing, was first published in 1995. Based on their evidence and previous studies
examining soluble forms of EGFR and other RTKs, the authors theorized that sAXL
acted as an regulator of full-length RTK function by binding the receptor’s natural ligand
and down-regulating its signaling function93. Further studies confirmed that cleavage of
the extracellular domain of AXL can serve as a dual-function regulator of AXL signaling
activity. By releasing the ligand binding domain, sAXL prevents the initiation of
dimerization94 and it can bind Gas6 in the ECM, further preventing initiation of the
signaling cascade78.
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Evidence has been put forward to suggest the important role this regulatory
mechanism may play in malignant diseases. As reported by Miller et al., 94 certain kinase
inhibitors can cause reduced ADAM-mediated RTK cleavage, including AXL, and was
inversely correlated with progression-free survival in a cohort of melanoma patients. In
this study, the use of mitogen-activated-protein-kinase (MAPK) inhibitors showed
significantly decreased proteolytic cleavage of AXL, MET and HER4. In melanoma
xenograft models, the inhibition of TIMP1, the natural inhibitor of ADAM proteins,
restored sheddase activity. When combined with MAPK inhibition, there was a
synergistic effect, resulting in a reduction of tumor growth and metastasis94.
Due to the demonstrable link between AXL overexpression and various diseases,
numerous studies have examined localized AXL tissue expression and the release of
sAXL as potential means of detecting diseases or monitoring treatment. Elevated sAXL
levels have been seen in chronic liver diseases such as liver fibrosis and cirrhosis95,96 and
hepatocellular carcinoma 95–98. Another significant study demonstrated a strong
association between sAXL and tumor progression, as well as patient survival, in renal
cell carcinoma 99. Similar studies have connected sAXL, or its natural ligand Gas6, to a
myriad of other diseases or physiological conditions such as melanoma100, ovarian
carcinoma92, systemic lupus erythematosus89,101,102, large abdominal aortic aneurysms 88,
severe preeclampsia 103,104, tumor burden in Neurofibromatosis Type 1 105, myocardial
infarction87 and heart failure106,107. A possible correlation exists between sAXL and GBM
however, based on available records, direct evidence of this has not been reported. This
project will be the first to investigate the possible distinctive presence of circulating
sAXL in GBM.
8

Figure 1: AXL Signaling Pathway Overview

(Top Left) Illustrations representing the immunosuppressive effects of AXL activation in several
types of immune cells. (Bottom Right) Simplified illustration showing the general phenotypic
expressions that result from AXL activation and downstream signaling through several significant
pathways. Taken from “Giving AXL the Axe: Targeting AXL in Human Malignancy” Gay CM,
Balaji K, Byers LA. Br J Cancer Lond. 2017;116(4):415-423.
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Figure 2: Regulating RTK Signaling Through Sheddase Activity

(A) Illustration representing ADAM-dependant sAXL shedding as a means ofdisrupting the
AXL/Gas6 complex, therefore dampening the effects of AXL signaling. (B) Inhibition of ADAM
proteins bypasses this regulation of AXL, leads to the accumulation of ADMA-related RTK
proteins and serves to amplify signaling cascades.
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AIMS AND GOALS

Glioblastoma lethality is in part due to the aberrant molecular signaling pathways
facilitated by RTKs. The RTK AXL promotes malignant phenotypes in GBM and other
cancers through myriad intracellular signaling pathways. Due to a unique type of
regulatory mechanism, facilitated by ADAM10 and ADAM17, the extracellular portion
of AXL is found circulating in the blood. This is true in the case of cancer patients and
healthy populations alike. The aim of this study is to compare the relative abundance of
sAXL in the blood of GBM patients and healthy volunteers then to use this as a means of
establishing sAXL as a novel biomarker for GBM.
I hypothesized that circulating sAXL in blood serum collected from GBM
patients would be elevated compared to a volunteer control population. I further
hypothesized that sAXL levels in samples collected after surgery would be lower than
paired samples collected prior to surgical intervention. It was also predicted that a change
in circulating sAXL levels would be reflected in samples collected while patients were
undergoing chemo- and radiation therapy. Lastly, I hypothesized that circulating sAXL
levels would reflect AXL expression in corresponding tumor tissue as well as tumor
volume calculated from contemporary MRI scans.
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METHODS AND MATERIALS

Obtaining Blood Serum Samples
Blood serum samples from 29 Northern Michigan University undergraduate
students enrolled in CLS 100 (phlebotomy) were a generous gift provided for this
research during the Winter 2019 semester. Blood samples were collected during the
course while practicing basic phlebotomy techniques. Samples were collected in Goldtop serum separator tubes that were labeled with a de-identified number that
corresponded to each student along with their age and sex. Tubes were centrifuged at
1000 rpm for 5-10 minutes then the supernatant was collected and aliquoted into 0.65 mL
Eppendorf tubes. Tubes were labeled and stored at -80° C. To expand this control
population, approval from Northern Michigan University’s Institutional Review Board
(IRB) was obtained in order to recruit 13 faculty members to donate blood for this study.
A student, experienced in phlebotomy, obtained the samples and used similar labeling as
described to maintain volunteer confidentiality. These blood serum samples were treated
as described previously.
Approval from the Aurora Health Care IRB was obtained for the collection of
blood serum, tissue specimens, and supplemental research information. Blood serum
samples were collected from GBM patients undergoing surgery at Aurora St. Luke’s
Hospital in Milwaukee Wisconsin. Of the 27 patients enrolled in the study, 23 of them
had confirmed GBM tumors by the Hospital’s pathology lab. Blood serum samples from
these patients were collected before surgery, after surgery, and up to 7 time points
12

corresponding with follow-up visits approximately every three months. These samples
will hereafter be referred to as pre-operative, post-operative, and BL1-7, respectively. A
sum of 84 GBM samples from 23 GBM patients was acquired for this study. Half of
these were from the pre- and post-operative time points, the other half from the bimonthly “treatment timeline”. Of the 42 pre- and post-operative samples, 38 were
collected from the same patient before and after surgery. All samples were labeled with a
de-identified number and the corresponding time point.
Dilution Scheme for Serum Samples
The blood samples were prepared as 1:200 dilutions, resulting in two
500µL aliquots by a two-step serial dilution in both Low-Cross Buffer™ (Candor
Biosystems) or Phosphate Buffered Saline (Dulbeco). These samples were stored at
-80°C for subsequent testing. Additionally, three 50µL aliquots of blood serum were
stored to mitigate freeze-thaw cycles of the original blood samples. These smaller
aliquots would be used for BCG assays to determine the total serum Albumin
concentrations while the 1:200 dilutions in either LCB or PBS would be used for either
ELISA or BCA assays respectively.

13
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Figure 3: Serum Dilution Scheme.

The general plan used to mitigate freeze-thaw cycles and inter-assay variation caused by dilution.
From the same serum sample, multiple aliquots were prepared in LCB (1:200), PBS (1:200) or
undiluted for the three assays to be implemented (ELISA, BCA and BCG).
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Preparation of Human AXL ELISA Kit
Human AXL DuoSet ELISA kits (R&D Biosystems) were purchased along with
the corresponding Ancillary Reagent Kits (DY008). The AXL capture and detection
antibodies were allowed to sit at room temperature for 15 minutes prior to diluting in
PBS, aliquoting in single-use portions and storage at -80° C. Following the
manufacturer’s instructions, 1mL of PBS was added to the vial containing capture
antibody in order reconstitute it, resulting in a 360µg/mL stock solution which was
sufficient antibody for at least 15 assays. Similarly, the detection antibody vial was
reconstituted with 1mL of reagent diluent (1% BSA in PBS, pH 7.2-7.4, 0.2uM filtered),
resulting in a 9µg/mL solution that was sufficient to perform at least 15 assays. The
recombinant AXL protein standards came in three separate vials containing 80ng of
lyophilized protein each. After warming to room temperature, one vial was reconstituted
in 500µL of room temperature LCB to a final stock concentration of 160ng/mL. Each
solution was aliquoted into single-use quantities and stored at -80° C. The streptavidinHRP solution came in a light-resistant vial and was stored undiluted at 4° C As a part of
my optimization of the ELISA protocol, the working concentration standards were later
prepared in one large serial dilution to the final concentrations of 4000, 2000, 1000, 500,
250, 125, 62.5 and 0 pg/mL in LCB at a final volume of 6mL each. These solutions were
then split into 14 aliquots and frozen at -80° C. This would ensure that all samples are
being compared to the exact same standards despite repetitions being performed on
separate dates.
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Enzyme-linked Immunosorbent Assay
The night before each assay, an aliquot of AXL capture antibody was thawed on
ice and was diluted 1:180 in PBS, to a final volume of 10mL at a concentration of 2.0
µg/mL. Using an 8-well multichannel pipette, 100µL of this solution added to each well
of a 96-well plate provided with the ancillary reagent kits. The plate was sealed with a
transparent adhesive strip, centrifuged briefly at 3000rpm to ensure even coating of all
wells. The plate was then allowed to sit at room temperature overnight on an even
surface.
The following morning, the plate was inverted to expel the solution into a waste
container and blotted against a clean paper towel. The plate was then washed three times
with 300µL of wash buffer (0.05% tween® 20 in PBS, pH 7.2-7.4), inverting, and blotting
the plate against a clean paper towel each time to ensure complete removal of fluid. The
plate was then blocked by adding 300µL of reagent diluent to each well and allowed to
sit at room temperature for 2 hours. During this time, diluted samples in LCB and diluted
AXL standards were thawed on ice, vortexed, and centrifuged briefly to ensure even
distribution. Next, 160µL of each sample was transferred to a designated 96-well
“transfer plate”, mirroring the intended locations on the ELISA plate. Using a “transfer
plate” rather than pipetting individual samples into 94 wells served to minimize any
variation of sample volume added between wells and exposure time to capture antibody.
After the blocking step, the plate was washed three times exactly as before. Using the 8well multichannel pipette, 100µL was transferred from each column of the “transfer
plate” to the ELISA plate, changing tips for each set of samples. The plate was
centrifuged briefly to ensure even distribution of the samples and allowed to incubate at
17

room temperature for 2 hours. The wash step was then repeated as before. This was
followed by the addition of 100µL of AXL detection antibody (50.0 ng/mL) to each well
using a multichannel pipette. The plate was centrifuged briefly and allowed to incubate
for 2 hours. Following another wash step, 50 µL of Streptavidin-HRP was warmed to
room temperature and diluted 200-fold in reagent diluent. Then 100µL of this solution
was added to each well and allowed to incubate for 20 minutes. The plate was washed
and then coated with 100 µL of a 1:1 mixture of color reagent A (hydrogen peroxide) and
color reagent B (tetramethylbenzidine). After a 20-minute incubation, the reaction was
halted by the addition of 50µL of stop solution (2N sulfuric acid). The plate was
immediately transferred to a spectrophotometer to measure the optical density of each
well at two wavelengths, 450 and 540nm. The 540nm measurement was used as a
wavelength correction by subtracting these values from the 450nm values. After adjusting
for background values by normalizing against the blanks, a four-parameter logarithmic
curve-fit was generated in GraphPad Prism based on the standard curve and use to
interpolate the concentrations of the samples. Standards on each plate were tested in
duplicate and each sample was tested in triplicate and repeated at least once, either on a
separate day or on a duplicate plate.
Optimizing the AXL ELISA for Ideal Interassay Variation
In the earliest stages of this project, samples were tested only once in triplicate but
due to early results suggesting promise for this assay it was decided that repeating
measures would offset limited sample availability as well as demonstrate another critical
assay performance characteristic, inter-assay variation. However, repeating the assay on
separate dates revealed an objectively high level of inter-assay variation, calling into
18

question the results of our previously collected data. To counteract this phenomenon,
several strategies were implemented, the first of which included preparing the samples in
the appropriate buffers and dilutions prior to testing and storing them at -80°C as
duplicate aliquots (see figure 3).
A simple experiment was first implemented to ensure that storing the diluted
samples at -80° C would not affect protein interpolated concentrations. For 13 randomly
selected serum samples, 1:200 dilutions in LCB and PBS and three smaller, undiluted,
aliquots were prepared. These samples were stored together at -80° C until the day of
testing. On the day of testing, the previously undiluted samples were prepared identically
to its counterpart samples and tested for sAXL and total protein using the standard
ELISA and BCA protocols, respectively. Samples diluted on the day of testing and those
stored frozen collectively showed no significant difference in protein concentration in
either the ELISA (figure 4) or BCA assay (figure 5).
All samples were then prepared as seen in Figure 3, however, after the first
ELISA was performed it was evident that the inter-assay variation was still present
(figure 6). From the protein stability experiment, it became apparent that the most
significant missing variable was the standards to which the diluted samples were
compared. Afterward, a batch preparation of AXL recombinant protein standard was
serially diluted but, on a scale, large enough to perform each of the remaining ELISAs
twice. The diluted standards were aliquoted and stored at -80° C together and thawed on
the day of testing. Together, preparing the diluted samples and standards resulted in a
drastically reduced inter-assay variation and was confirmed by a paired t-test (figure 7).
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Bicinchoninic Acid (BCA) Assay to Determine Total Serum Protein
Samples diluted 1:200 in PBS were thawed on ice, mixed via vortex and
centrifuged briefly. BCA standards (Thermofisher) previously were prepared at
concentrations of 2000, 1500, 1000, 750, 500, 250, 125, and 0 µg/mL in molecular grade
water. After samples and BCA standards were warmed to room temperature, 50µL of the
standards were added to a transfer plate in duplicate. Next, 100µL of the diluted samples
were added to the plate in triplicate, mirroring the sample layout used in the ELISA
experiments. Using an 8-well multi-channel pipette, 25 of each sample was transferred to
a clean 96 well plate, one column at a time. Next, 200µL of a mixture of BCA reagents A
and B (1:50) was added to each well. After a 30-minute incubation at room temperature,
the plate was measured for optical density at 562nm. Standards used were tested in
duplicate and each of the samples was tested in triplicate. Concentrations were
interpolated from a standard curve, adjusted by the dilution factor, and were converted
from µg/mL to g/dL by dividing by a factor of 10,000.
Bromocresol Green (BCG) Assay to Determine Total blood albumin
Frozen aliquots of blood serum were thawed on ice, diluted 1:2 in ultra-pure
water, and transferred to a 96-well plate. Frozen BSA standards at concentrations of 5, 4,
3, 2, 1.5, 1, 0.5, and 0 g/dL were thawed on ice and transferred to the 96-well plate. Next,
200µL of BCG reagent was added to each well and incubated for five minutes at room
temperature. The plate was then read for optical density at 620nm. Using GraphPad
Prism, a four-parameter logarithmic curve-fit was generated and used to interpolate the
sample concentrations. Standards used were tested in duplicate and each sample was
tested in triplicate. The BCG assay functions as a specific quantitative measurement of
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albumin due to the formation of a chromophore upon the interaction of BCG and
albumin.
Tissue Sonication
Frozen tumor tissue samples that were acquired were obtained by the ARI
Biorepository and Specimen Resource Center (BSRC) who stored them at -80° C until
ready for transfer to the ARI lab. Frozen tissues were briefly thawed on ice prior to being
transferred to a sonication tube, also on ice, with clean forceps. The original tubes were
rinsed with ice-cold RIPA buffer containing protease inhibitors and transferred to the
sonication tube. Tubes were weighed before and after to determine tissue mass. Ice-cold
RIPA buffer was added to a final volume of 500 µL in each tube. Samples were then
sonicated twice at 10% amplitude for 10 seconds and three times at 15% amplitude or
until the homogenate became transparent. Samples were immediately placed back on ice
in between sonication bursts and great care was taken to keep the sonication probe in the
middle of the mixture to avoid frothing. These homogenates were subsequently
centrifuged at 14,000 rpm at 4° C for 10 minutes to pellet any insoluble material. The
remaining supernatant was removed with a pipette, and 50 µL aliquots were stored at 80° C.
Western Blotting
Protein concentration for each of the 15 tumor lysates was determined by BCA
assay (Thermofisher) using minimal lysate (10µL/ well). Using the interpolated
concentration was then used to calculate the volume needed to load 40ug of total protein
per well. Ice-cold RIPA buffer was used to normalize the volume and a consistent
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amount of 4x LSB (BioRad) containing 10% β-mercaptoethanol was added to each tube.
Samples were denatured at 95° C for 5 minutes and immediately chilled on ice.
Denatured samples were loaded in a 4-12% Criterion™ Bis-Tris gel (BioRad) and ran at
80v for approximately 1.5 hours. The proteins were transferred to a PVDF membrane
using the iBlot® 2 (Thermofisher) semi-dry transfer system. The membrane was blocked
in 5% molecular grade NFDM blocking buffer (BioRad) for 1 hour. It was then washed
three times for 5 minutes in 1x TBS (BioRad). The membrane was covered in 5%
blocking buffer containing AXL antibody diluted 1:200 and incubated overnight at 4° C
on a shaker. The next morning the membrane was washed three times in TBST (0.1%
tween) for 10 minutes. Secondary, mouse anti-goat, antibody diluted 1:2000 in blocking
buffer was added to the membrane and was allowed to incubate for one hour (RT), with
shaking. The membrane was washed as before and developed by covering it drop-wise
with a 1:1 mixture of clarity peroxide reagent and clarity luminol reagent (BioRad) and
incubating for five minutes. The blot was then immediately transferred to a LiCore
imaging system and read for 2 minutes on the chemiluminescent channel and 5 minutes
on the 700nm channel. The membrane was then stripped of antibodies by coating the
membrane in OneMinute® Stripping Buffer (GM Biosciences), blocked for one hour in
5% NFDM and washed three times in TBST (0.1% Tween20). The membrane was coated
in an rabbit anti-actin primary antibody (1:2000 in 5% NFDM) incubated overnight at 4°
C on a shaker. The following morning the membrane was washed three times for 10
minutes in TBST (0.1% Tween20). The membrane was then coated in anti-rabbit
secondary antibody (1:2000 in 5% NFDM) for 1 hour at room temperature. This was
followed by three washes for 10 minutes in TBST (0.1% Tween20). The membrane was
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then developed by covering it drop-wise with a 1:1 mixture of clarity peroxide reagent
and clarity luminol reagent (BioRad) and incubating for five minutes at room
temperature. The blot was then immediately transferred to a LiCore imaging system and
read for 2 minutes on the chemiluminescent channel and 5 minutes on the 700nm
channel.
Pre-Operative MRI analysis
MRI scans taken for each of the 27 enrolled patients were completely deidentified and made available in BrightMatter Plan (Synaptive Medical, Toronto, CAN),
the software used by Aurora St. Luke’s to plan surgeries. Training in the software was
conducted by an experienced neuroradiologist, how to distinguish tumor tissue from other
enhancing regions of the brain. BrightMatter Plan was used to analyze all of the preoperative T-1 weighted scans of the patients and build a 3D model of the tumor. The
software automatically calculates the tumor volume. Each analysis was reviewed and
modified when necessary to ensure their accuracy.
Data Analysis
Determination of statistically significant variation between two groups was
performed using a two-tailed, unpaired student’s t-test unless noted otherwise. For
datasets with three or more groups were analyzed using repeated measures, mixed-model,
one-way ANOVA with Dunnett’s post hoc. Graphical representation of datasets were
performed in GraphPad with error bars representing either 95% confidence intervals or
mean ± SEM unless noted otherwise.
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RESULTS
Characterizing sAXL in GBM and Healthy Control Populations
It was hypothesized that sAXL would be significantly elevated in patients with
GBM as a result of elevated membrane AXL release from tumor tissue as a result of
enzymatic cleavage. Investigating this in the broader sense meant performing ELISAs on
GBM and control samples using the optimized methodology previously mentioned. Since
the sample size was somewhat limited compared to other studies investigating protein
biomarkers, a somewhat larger data set was generated by testing each sample in triplicate
and on two separate occasions. Including other variables, such as serum albumin or total
serum protein, would also allow for a more powerful statistical analysis of these two
populations. After testing 124 samples as previously described, sAXL was found to be
significantly elevated in the GBM population (35.77 ± 1.25, n=84) compared to the
healthy population (30.16 ± 1.88, n=40; p = 0.013) (Figure 8). Upon further comparison
of each population, normalizing the sAXL values against serum albumin (Figure 11) and
total protein (Figure 12), the distinction became even more apparent in both cases
(P < 0.0001). This increased distinction was due to the finding that GBM patients had
significantly lower serum albumin (P < 0.0001) (Figure 9) and total serum protein (P <
0.0001) (Figure 10) compared to the control population. Additionally, sorting the samples
by gender in each category (healthy or GBM), no significant difference was seen in any
group as determined by a one-way ANOVA (Figure 13).
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Figure 4: Protein Stability Test: ELISA

sAXL concentrations (ng/mL) for paired samples previously diluted and stored at -80°C
(33.8±3.24, n=13) versus samples prepared the day of testing (34.06±3.52, n=13). Statistical
significance of variation was calculated using a two-tailed, paired student’s t-test. Concentrations
and error bars presented as mean ± SEM.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Figure 5: Protein Stability Test: BCA assay

Total protein concentrations (g/dL) for paired samples previously diluted and stored at -80°C
(6.17±0.26, n=12) versus samples prepared the day of testing (6.41±0.20, n=12). Statistical
significance of variation was calculated using a two-tailed, paired student’s t-test. Concentrations
and error bars presented as mean ± SEM.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Figure 6: ELISA Inter-assay Variation: Individual Protein Standards

Sample ID vs. sAXL concentrations for samples prepared and stored identically then tested on
two separate dates. AXL recombinant protein standards used were prepared on the day of testing.
Statistical significance of variation was calculated using a two-tailed, paired student’s t-test. Error
bars presented as mean ± SEM.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Figure 7: ELISA Inter-assay Variation: Batch-Prepared Protein Standards

Sample ID vs. sAXL concentrations for samples prepared and stored identically then tested on
two separate dates. AXL recombinant protein standards used were prepared as a batch and
aliquoted for multiple tests. Statistical significance of variation was calculated using a two-tailed,
paired student’s t-test. Error bars presented as mean ± SEM.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Table 1: sAXL Summary Data
Sample Type

N

Healthy

(n=40)

sAXL (ng/mL)
30.16±1.88

Albumin (g/dL)
5.89±0.16

sAXL/Albumin Ratio
5.38±0.44

F

(n=27)

28.67±1.92

5.86±0.17

5.09±0.46

M

(n=13)

33.26±4.2

5.97±0.35

6±0.98

GBM

(n=84)

36.31±1.45

4.24±0.07

8.68±0.34

F

(n=26)

30.16±1.88

4.39±0.11

7.94±0.51

M

(n=58)

34.57±2.46

4.17±0.08

9.01±0.44

Pre-Op

(n=20)

30.74±1.96

4.35±0.12

7.28±0.56

F

(n=8)

29.22±3.35

4.25±0.17

6.66±0.85

M

(n=12)

31.75±2.48

3.92±0.14

7.69±0.75

(n=22)

Post-Op

32.32±2.26

8.87±0.73

3.76±0.1

F

(n=9)

29.61±2.48

3.92±0.14

7.74±0.73

M

(n=13)

34.2±3.4

3.65±0.13

9.66±1.1

BL1

(n=9)

39.42±4.73

4.83±0.14

8.31±1.16

F

(n=3)

48.52±9.6

4.97±0.14

9.89±2.28

M

(n=6)

34.87±4.77

4.77±0.21

7.52±1.35

(n=6)

BL2

49.11±6.98

4.32±0.29

11.52±1.57

F

(n=1)

66.3±0

5.35±0

12.39±0

M

(n=5)

45.68±7.44

4.11±0.24

11.35±1.91

(n=7)

BL3

38.77±3.86

4.34±0.19

9.12±1.09

F

(n=1)

29.29±0

4.55±0

6.43±0

M

(n=6)

40.35±4.17

4.3±0.22

9.56±1.18

BL4

(n=6)

40.32±1.75

4.18±0.3

10.03±1.11

F

(n=2)

36.56±2.8

4.25±0.47

8.78±1.63

M

(n=4)

42.21±1.67

4.14±0.43

10.66±1.5

BL5

(n=6)

35.81±3.4

4.38±0.23

8.35±1

F

(n=1)

34.92±0

4.74±0

7.37±0

M

(n=5)

35.99±4.16

4.3±0.26

8.55±1.2

BL6

(n=3)

45.42±3.57

4.48±0.22

10.18±0.86

F

(n=1)

49.37±0

4.89±0

10.11±0

M

(n=2)

43.45±5.16

4.27±0.11

10.22±1.48

(n=5)

BL7

32.95±4.56

4.32±0.39

7.95±1.6

F

(n=0)

0±0

0±0

0±0

M

(n=5)

32.95±4.56

4.32±0.39

7.95±1.6

Descriptive statistics table outlining concentrations of sAXL (ng/mL), Albumin (g/dL) and the corresponding
ratio between them. Groups first separated based on cohort (GBM vs. Healthy), further separated based on
collection time points and then by gender.
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Figure 8: sAXL in GBM and Healthy Blood Serum

Serum sAXL concentrations are elevated in GBM patient samples (35.77 ± 1.25, n=84) compared
to healthy volunteer samples (30.16 ± 1.88, n=40; p = 0.013). Grouped sAXL concentrations are
listed as mean ± SEM. Violin plots above represent the group median (solid line) and quartiles
(dashed lines). Statistical significance of variation was calculated using a two-tailed, unpaired
student’s t-test.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Figure 9: Serum Albumin in GBM and Healthy Blood Serum

Serum albumin concentration are elevated in the healthy volunteer samples (5.89 ± 0.16, n=40)
compared to the GBM patient samples (4.235 ± 0.07, n=84) (P < 0.0001). Collective Albumin
concentrations are listed as mean ± SEM. Violin plots above represent the group median (solid
line) and quartiles (dashed lines). Statistical significance was calculated using a two-tailed,
unpaired student’s t-test.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Figure 10: Total Protein in GBM and Healthy Blood Serum

Total protein concentration are elevated in the healthy volunteer samples (7.43 ± 0.15, n=40)
compared to the GBM patient samples (5.98 ± 0.093, n=74) (P < 0.0001). Collective total protein
concentrations are listed as mean ± SEM. Violin plots above represent the group median (solid
line) and quartiles (dashed lines). Statistical significance was calculated using a two-tailed,
unpaired student’s t-test.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Figure 11: sAXL/Albumin Ratio in GBM and Healthy Blood Serum

Values from each sample’s measured sAXL concentration normalized against the average of the
corresponding serum albumin concentration for each sample. Ratios for GBM patient samples
(8.68 ± 0.34, n=84) are elevated compared to the healthy volunteer samples (5.38 ± 0.44, n=40)
(P < 0.0001). Collective ratios are listed as mean ± SEM. Violin plots above represent the group
median (solid line) and quartiles (dashed lines). Statistical significance was calculated using a
two-tailed, unpaired student’s t-test.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Figure 12: sAXL/Total Protein Ratio in GBM and Healthy Blood Serum

Values from each sample’s measured sAXL concentration normalized against the average of the
corresponding total protein concentration for each sample. Ratios for GBM patient samples (6.20
± 0.23, n=74) are elevated compared to the healthy volunteer samples (4.14 ± 0.23, n=40) (P <
0.0001). Collective ratios listed as mean ± SEM. Violin plots above represent the group median
(solid line) and quartiles (dashed lines). Statistical significance was calculated using a two-tailed,
unpaired student’s t-test.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Figure 13: Serum sAXL Concentration in Males and Females Separated by GBM
Status

Serum sAXL concentrations for healthy (solid fill) and GBM (diagonal pattern) samples
separated by male (blue) and female (red). Concentrations were not significantly different
between genders in either the healthy or GBM cohorts. Error bar represent 95% confidence
interval. Statistical significance of variation was calculated using a one-way ANOVA.
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Using sAXL as a Predictive Biomarker for GBM Presence
In order to test the hypothesis that sAXL was a predictive biomarker for the
presence of GBM, pre-operative serum samples (as opposed to all the GBM serum
samples) were compared to the healthy controls. First, comparing sAXL in the preoperative and post-operative samples to the healthy control would serve to distinguish
sAXL as a marker for the presence of GBM at the point of surgery. However, considering
only sAXL, neither the pre-operative or post-operative samples compared to the healthy
control showed a significant difference (Figure 14). Making this same comparison with
serum albumin alone showed that healthy samples had elevated concentrations of serum
albumin as compared to both groups (P < 0.0001) (Figure 15). For this reason,
normalizing sAXL against serum albumin was able to distinguish sAXL in both preoperative (P = 0.013) and post-operative populations (P < 0.0001) from the control
population (Figure 16). This suggests that sAXL concentration is not sufficient to predict
GBM presence but comparisons to other serum proteins may be sufficient in making the
distinction between these populations.
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Figure 14: sAXL Concentrations: Control, Pre-operative and Post-operative
samples

Serum sAXL concentrations are not elevated in pre-operative (30.84 ± 2.07, n=19) or postoperative samples (32.04 ± 2.44, n=19) compared to the healthy control samples
(30.16 ± 1.88, n=40). Similarly, sAXL concentrations did not significantly change in response to
surgery. Concentrations for each group are listed as mean ± SEM. Violin plots above represent
the group median (solid line) and quartiles (dashed lines). Statistical significance between healthy
and GBM samples were calculated using an unpaired t-test. Statistical significance between
paired GBM samples was calculated with a paired t-test.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Figure 15: Serum Albumin Concentration: Control, Pre-operative and Postoperative samples

Serum albumin concentrations are significantly elevated in the healthy control population
(5.89 ± 0.16, n=40) compared to both pre-operative (4.34 ± 0.12, n=19) (P < 0.0001) and postoperative samples (3.70 ± 0.10 n=19) (P < 0.0001). Additionally, serum albumin concentrations
are elevated in the pre-operative samples compared to post-operative samples (p = 0.0002).
Concentrations for each group are listed as mean ± SEM. Violin plots above represent the group
median (solid line) and quartiles (dashed lines). Statistical significance between healthy and
GBM samples were calculated using an unpaired t-test. Statistical significance between paired
GBM samples was calculated with a paired t-test.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Figure 16: sAXL Normalized by Albumin: Control, Pre-operative and Postoperative samples

Serum sAXL concentrations normalized by albumin concentrations from the healthy control
(5.384 ± 0.44, n=40), pre-operative (7.32 ± 0.59, n=19) and post-operative samples
(8.84 ± 0.77, n=19). Values calculated as a ratio between individual sAXL concentrations and the
mean albumin concentration for each sample, collectively listed as mean ± SEM. Violin plots
above represent the group median (solid line) and quartiles (dashed lines). Statistical significance
between healthy and GBM samples were calculated using an unpaired t-test. Statistical
significance between paired GBM samples was calculated with a paired t-test.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

39

Serum sAXL in Response to Surgical Intervention
Since the first step in the treatment of GBM is the maximal amount of tumor
resection, it would follow that removal of sAXL releasing tumor tissue should result in an
overall reduction in serum sAXL following surgery. It was shown that pre-operative
samples tested only for sAXL showed no significant difference compared to the healthy
controls (Figure 14), but when normalizing by serum albumin a distinction was made
(Figure 16). Despite this, it became apparent that there was no significant difference in
sAXL as a result of surgical intervention, in roughly half the patients sAXL levels rose
and in the other half, they fell with no noticeable trend (Figure 17). However, performing
this same comparison with sAXL concentrations normalized to serum albumin showed a
distinct upward trend as determined by a two-tailed, paired t-test between the 19 matched
samples (P = 0.019) (Figure 18). Moreover, an interesting correlation appeared from
this dataset when interpolated tumor volumes were included in the analysis. To represent
the change in sAXL between each time point, pre-operative sAXL values were subtracted
from their corresponding post-operative values (n=19). These values were then plotted
against pre-operative tumor volume, fit with linear regression and evaluated for a
correlation using the Pearson method (Figure 19). The result was a significant correlation
(P = 0.013) between tumor volume and net change in circulating sAXL. The trend
shows that after surgery, patients with larger tumors tended to result in a net increase in
sAXL after surgical intervention and smaller tumor volumes tended to result in a net
decrease in sAXL.
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Figure 17: Change in Serum sAXL: Pre-Post Surgery

No significant change is seen in response to surgery as determined by a two-tailed, paired t-test.
Individually matched serum sAXL concentrations from patient samples before (n=19) and after
(n=19) surgery. Each dot represents the average of 6 replicates and each line connects the paired
samples.
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Figure 18: Change in Normalized Serum sAXL: Pre-Post Surgery

Serum sAXL/albumin ratios are significantly elevated after surgery (P = 0.019) as determined by
a two-tailed, paired t-test. Each dot represents the average of 6 replicates and each line connects
the paired samples. Individually matched serum sAXL concentrations from patient samples
before (n=19) and after (n=19) surgery.
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Figure 19: Pre-opertaive Tumor Volume vs. Change in sAXL
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Elevation in serum sAXL levels observed after surgery directly correlates with tumor volume.
Solid blue line represents best-fit line determined by standard linear regression. Dotted line
represents baseline, no change, in sAXL. Correlation (r) and significance (P) values calculated
using Pearson method.
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Serum sAXL in Response to Treatment
Looking past the point of surgery (ie. Post-operative time point) to the treatment
time points was attempted to test the hypothesis that sAXL was capable of tracking
disease progression and treatment response. It can be seen that the number of samples
acquired by each patient during this phase dropped precipitously. Despite this, it is also
apparent that sAXL tended to be at its highest during the period following surgery once
standard treatment regimens had begun (Table 1, figure 20). However, upon
characterizing the treatment timeline samples and comparing against the post-operative
samples did not showed any significant effect as determined by a mixed-model one-way
ANOVA (Figure 20). Similar to previous comparisons, sAXL concentrations were
normalized against serum albumin but did not show any significant effect in treatment
timeline samples from the healthy controls and the surgical samples as determined by a
mixed-model one-way ANOVA (Figure 21). Together these data suggest, but cannot
confirm, that the significant elevation of sAXL in the GBM population as a whole
compared to the control population (Figure 8), is primarily in response to either treatment
or disease progression.
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Figure 20 : sAXL at Each Treatment Timepoint and Post-operative Samples

Serum sAXL concentrations from GBM patient samples, separated by treatment time point
showed no significant effect compared to the post-operative samples. Violin plots above represent
the group median (solid line) and quartiles (dashed lines). Statistical significance of variation for
paired samples was calculated using a mixed-model one-way ANOVA.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Figure 21: sAXL Normalized by Albumin at Each Timepoint and Postoperative
Samples

Serum sAXL concentrations normalized by serum albumin from GBM patient samples, separated
by treatment time point showed no significant effect compared to the post-operative samples.
Values calculated as a ratio between individual sAXL concentrations and the mean albumin
concentration for each sample. Violin plots above represent the group median (solid line) and
quartiles (dashed lines).Statistical significance of variation for paired samples was calculated
using a mixed-model one-way ANOVA.
ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
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Associations between sAXL, AXL and Tumor Volume
In all, 16 tissue samples were made available for western blotting. Of these, 14
were GBM, one was an astrocytoma, and one was a tumefactive demyelinating process
(MS). One of the GBM tissue samples was so small, a high enough concentration of
protein could not be extracted for western blotting. With the remaining 15 samples, the
protein concentration of the homogenates was estimated using BCA assays. Next, 40 µg
of protein was loaded in a 4-12% Criteron™ Bis-Tris gel (BioRad), and separation of
protein was achieved via gel electrophoresis and transferred to a PVDF membrane. This
membrane was then blocked in 5% NFDM blocking buffer and blotted for AXL (1:2000)
and β-Actin (1:2000). The membranes were developed using BioRad chemiluminescent
substrate solutions, imaged and analyzed using Image Studio software (Li-COR
Biosciences) (Figure 24). The optical density (OD) of the bands was interpreted and by
dividing the AXL O.D by the actin OD, a value representing relative AXL expression
was obtained.
Pre-operative tumor volumes for all 23 GBM patients enrolled in the study were
determined using de-identified T1-weighted MRI scans using BrightMatter Plan software
(Figure 25). This was done by scrolling up and down through the axial plane of the scans,
highlighting enhancing regions with the brush tool that logically corresponded to tumor
tissue (i.e. excluding ventricles and apparent blood vessels). All analyses were reviewed
and when necessary edited, by a board-certified neuroradiologist. All scan files were
labeled with the de-identified number and time point that corresponded with its matched
serum sample. Tumor volumes interpolated from these scan files were transcribed by
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hand, cross-checked, and manually transferred into a composite sAXL excel spreadsheet
used to perform all statistical analyses.
Determining correlations between membrane AXL (mAXL) was performed using
GraphPad software by inputting matched patient data, such as pre-operative sAXL and
membrane AXL expression values, then performing a correlation analysis using the
Pearson method. As a whole, comparing mAXL expression to pre-operative sAXL
concentrations yielded no clear correlation (r= 0.15) (Table 2). However, when patient
samples are broken into groups based on sAXL concentration, a new pattern emerged.
Similar to methods performed in Hutterer et al.45, those patients with pre-operative sAXL
concentrations ≥30 ng/mL (the average healthy sAXL concentration) were placed in the
“sAXL High” group and the remainder in the “sAXL Low” group. Repeating these
comparisons with each group then revealed a number of interesting correlations, the most
significant of which being pre-operative sAXL in the “high” group is directly correlated
with membrane AXL expression (r= 0.85) (Table 3, Figure 26).
A somewhat weaker correlation was made between pre-operative sAXL/albumin
ratio and mAXL (r= 0.65) (Table 2). Moreover, in the “Low” group, there were several,
moderate to strong, negative correlations made between mAXL and the following
characteristics: pre-operative sAXL, pre-operative sAXL/albumin ratio, post-operative
sAXL, post-operative sAXL/albumin ratio and pre-operative tumor volume (Table 2).
These negative correlations indicate that larger mAXL expression results in smaller
values in the corresponding variable. This is most interesting in the case of pre-operative
tumor volume as it suggests that in the largest tumors lies the greatest retention of AXL
on the plasma membrane, perhaps as a result of reduced proteolytic cleavage.
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Evaluating associations with pre-operative tumor volume was performed as
before but using volume as the dependent variable. In the collective GBM sample group
(n=13), the strongest correlation was a moderate one with post-operative sAXL/albumin
ratio group (Table 3). Once separated into “High” and “Low” groups, tumor volume
showed no strong correlations. Of the moderate correlations, tumor volume was
negatively correlated with pre-operative sAXL and normalized sAXL and positively
correlated with post-operative sAXL and normalized sAXL (Table 3) but only in the
“high” group. In the “low” group, volume was moderate-positively correlated with preoperative, post-operative sAXL values and as previously mentioned, mAXL expression
(Table 3). Based on the limited dataset, this suggests that the strongest associations lie
between tumor volume and mAXL, as well as between tumor volume and post-operative
sAXL/albumin ratio.
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Figure 22: Membrane sAXL Expression in GBM Tumor Lysates

Western blots for 15 tissue homogenates, 13 of which are GBM. Membrane AXL expression
found at ~140kDa (Top). Housekeeping gene, β-Actin expression for corresponding tissue
samples found at ~40kDa (Bottom). Optical densities of these bands were calculated using Image
Studio software (Li-COR Biosciences) and used to calculate relative AXL expression.
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Figure 23: T1 Weighted MRI Scan of GBM Tumor

Example of tumor volume analysis in BrightMatter Plan software. Enhancing regions showing
high contrast material uptake were highlighted using the brush tool in the transverse plane
(bottom left panel) at various increments of distance. Once layers of tumor were highlighted top
to bottom, tumor volume was interpolated, and a corresponding value would appear in the top
right section.
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Table 2: Associations with membrane AXL
All
n

‡

r

P

Post-op sAXL Ratio

11
11
13
13

-0.40
-0.27
-0.49
-0.42

Pre-op Tumor Volume

13

-0.33

†

pre-op sAXL
pre-op sAXL Ratio
post-op sAXL

sAXL-High
n

‡

r

P

0.23
0.43
0.09
0.15

6
6
7
7

0.85
0.65
-0.07
-0.06

0.28

7

-0.32

*

†

sAXL-Low
n

r‡

P*

0.03
0.16
0.88
0.90

5
5
6
6

-0.68
-0.56
-0.68
-0.60

0.20
0.33
0.14
0.21

0.48

6

-0.65

0.16

*

†

Pearson correlations between membrane AXL as determined by western blotting and other
patient sample characteristics separated into three groups, all samples with available tissue
samples, patients with high sAXL (≥30ng/mL) and patients with low sAXL (<30ng/mL).
† Number of comparisons made. ‡Pearson r value: ±0.3-0.7 is considered a moderate
correlation; > ±0.7 is considered a high correlation *P values: ≤0.05 is considered statistically
significant.
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Table 3: Associations with pre-operative tumor volume
All

sAXL-High

n

‡

n

‡

r

P

r

P

pre-op sAXL

11

0.15

0.65

6

-0.58

pre-op sAXL Ratio

11

0.09

0.80

6

post-op sAXL

13

0.32

0.29

Post-op sAXL Ratio

13

0.50

Membrane AXL

13

-0.33

†

sAXL-Low
n

r‡

P*

0.23

5

0.49

0.40

-0.31

0.55

5

0.17

0.78

7

0.32

0.48

6

0.48

0.34

0.08

7

0.55

0.20

6

0.48

0.34

0.28

7

-0.32

0.48

6

-0.65

0.16

†

*

*

†

Pearson correlations between pre-operative tumor volume and other patient sample
characteristics separated into three groups, all samples with available tissue samples, patients
with high sAXL (≥30ng/mL) and patients with low sAXL (<30ng/mL).
† Number of comparisons made. ‡Pearson r values: ±0.3-0.7 is considered a moderate
correlation; > ±0.7 is considered a high correlation *P values: ≤0.05 is considered statistically
significant.
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Figure 24: Pre-operative sAXL is Associated with Membrane AXL

The 11 patients with both tissue and pre-operative serum samples available were separated into
two groups, sAXL high (≥ 30 ng/mL, blue) and low (< 30 ng/mL, red) based on pre-operative
sAXL concentrations. The pre-op sAXL concentration for both of these groups were plotted
against relative AXL expression determined by western blotting. These values were fitted using
linear regression and correlations were calculated using the Pearson method.
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DISCUSSION

The receptor tyrosine kinase AXL has been well characterized with regard to its
implications in various types of cancer, including GBM. However, until now, the soluble
form of this protein (sAXL) resulting from the proteolytic cleavage by ADAM proteins
had yet to be explored as a potential biomarker for GBM. Due to the evidence that AXL
is frequently overexpressed in GBM and that the protein is subject to this unique form of
post-translational regulation resulting in its release into the circulatory system, it seemed
possible that this could serve as a means of detecting GBM in a minimally-invasive
manner.
While this study was able to generate some supporting evidence, we did not find
that sAXL can be used to predict the presence of GBM near disease onset. Granted, there
is a lack of uniformity in the reported values associated with circulating sAXL, in other
studies in other cancer types examining sAXL as a predictive biomarker. However, those
studies found a larger difference between the control and study populations. For example,
sAXL is highly elevated in a number of liver diseases. As reported by Dengler et al.9 in a
large multicenter study, sAXL was elevated in hepatocellular carcinoma (78.69 ng/mL,
n= 347) compared to healthy controls (40.15 ng/mL, n=75)97. Our results did not have
this pronounced difference between healthy and disease but showed some promise for
using sAXL as a biomarker for GBM, particularly when combined with multiple
variables.
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The systematic dilution scheme (see figure 3), where samples were stored diluted
in order to mitigate freeze-thaw cycles on the limited number of serum samples, showed
no significant effect on interpreted sAXL concentrations (see figure 4). This approach
was inspired by the Dengler et al.108 optimization study where they evaluated the stability
of sAXL when exposed to multiple freeze-thaw cycles. In the same study, they
demonstrated the necessity of performing a 1:200 dilution of serum in the proprietary
buffer LowCross™ buffer in order to effectively reduce the masking effect of proteinrich solutions like blood serum. However, due to high inter-assay variation, it was
necessary to prepare the AXL protein standards as a batch such that they very closely
mirror each other in assays performed on different days. This effectively increased the
assay’s precision as demonstrated by the dramatically reduced inter-assay variation (see
figures 6 and 7). Further optimization of the assay’s performance characteristics would
entail acquiring internal controls in the form of purified human AXL protein to assess the
reliability of the standards being used. Also, to address any concerns regarding accuracy,
having a set of samples tested at a separate facility using the same protocol would be a
means of bolstering the confidence of the results.
Here it was demonstrated that compared to a volunteer population, sAXL is
elevated in blood serum collected from GBM patients (see figure 8). While sAXL
concentration was able to distinguish the GBM and control populations in general, the
bulk of that difference came from the treatment time points, long after the disease had
become apparent. Incorporating a second characteristic, serum albumin, helped further
distinguish GBM from healthy controls in nearly all cases. When normalized against
serum albumin, the pre-operative values were significantly elevated compared to the
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control group but lower than that of the paired post-operative samples (see figure 16).
However, the use of albumin, which can change due to something as simple as being
properly hydrated, is not reliable without confirmation of these findings on a much larger
scale.
In order to bolster the predictive capacity of this sort of assay I would suggest
incorporating other proteins that are more relevant to tumor pathophysiology and are
similarly subject to sheddase activities. For example, CD147109, TNF110, or HER111
proteins all play significant roles in cancer cells and are also subject to post–translational
regulation in an ADAM-dependent manner. In this combinatorial approach as seen in
Miller et al.94, building a biomarker panel of tumor-relevant proteins could serve to
increase the predictive efficacy not achieved with sAXL alone or the sAXL/albumin
ratio. Implementing the protocol in an automated fashion or using another methodology
such as LC-MS could prove to be a more high-throughput approach, especially if it could
analyze multiple targets in a similar timeframe.
Initially, the lack of a distinct trend from pre- to post-operative samples suggests
that surgical intervention did not significantly impact sAXL levels in paired samples (see
figure 17). However, there was a modest elevation in sAXL/albumin ratio in these same
paired samples, suggesting that there was an impact but not significant enough to notice
by assessing sAXL alone (see figure 18). In general, the blood-brain barrier (BBB) is
known to be highly restrictive with respect to which macromolecules are able to pass.
This is partially due to the tight junctions that create a tight seal between the specialized
ependymal cells that make up the blood-brain barrier112. This is why only lipid soluble112
and very small molecules (i.e. <400 Da)113 are able to readily pass the BBB without
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active transport. While the BBB often has increased permeability in glioma for a number
of reasons114, there does not seem to have been any direct evidence that suggests sAXL is
restricted from or capable of crossing the BBB. In this study however, sAXL/albumin
ratios were elevated, instead of decreased, after surgery and the data that showed tumor
volume correlated with the net change in sAXL after surgery. One explanation for this
would be that the blood-brain barrier is hampering the release of sAXL in general but not
completely and only the largest tumors have produced such an excess of sAXL that it has
become “backed up” and is then released as a result of surgery. One way to test this
hypothesis would be to collect blood that is aspirated from the surgical site where the
tumor is located then compare it to blood serum collected contemporaneously from a
more peripheral blood vessel like the median cubital vein.
Theoretically, if sAXL were being released from the tumors in high enough
quantities to make up a noticeable portion of the total serum sAXL concentration, the
post-operative concentrations should have decreased relative to pre-operative values.
However, this is built upon the premise that circulating sAXL is cleared or filtered out
fast enough to notice a decrease in a timeframe of 24 hours. To date, there do not appear
to be any publications supporting or refuting this idea directly. A small number of urine
samples were collected from GBM patients and were tested for sAXL alongside the
serum samples. Interestingly, sAXL was highly elevated in one of the four samples (data
not shown), but did not seem related to either the pre-operative or post-operative samples
and seemed likely related to kidney issues as has been reported before91. One direction I
would venture in order to explore this idea would be to track the release of sAXL in
urine, which is found at similar concentrations as those reported for blood serum91,
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throughout the course of a day in order to assess a normal rate of sAXL release from the
body.
Considering that sAXL concentrations were highest during the treatment timeline,
the elevation could simply be due to upregulated AXL induced by chemotherapeutic
drugs as demonstrated in the past40. On the other hand, AXL has also been shown to be
upregulated in drug-resistant forms of numerous cancer subtypes40,67,94,115 and this could
be another example of that. This study, however, was not designed to evaluate the
prognostic potential of sAXL and therefore, the curious elevation seen during the
treatment timeline is a phenomenon left mostly unexplored. A retrospective study of
outcomes from the patients enrolled could be implemented to assess these effects.
Regardless, the results of this study suggest that on its own, sAXL would not serve as an
ideal predictor of GBM prior to the emergence of symptoms.
One of the most significant limitations in this study was the sample size and
collection consistency. Understandably, obtaining tissue specimens was not always
feasible because there is a prioritization hierarchy to which biopsied samples are made
available. First, the pathology department obtained whatever size specimen was needed
for diagnostic testing. Second, tissue samples were used to generate primary cell lines
and this study received whatever was left. Similarly, obtaining blood serum was not
always possible. In nearly every enrolled patient, some samples were missed due to
complications in the collection procedure, patients opting out of treatment, etc.
Additionally, it now appears that sonication on the tumor tissue samples likely resulted in
the degradation of proteins. Instead, a gentler, more precise method of protein extraction
should have been implemented. Using either an electric homogenizer or a simple
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dissociative agent, followed by differential centrifugation should have been used to
isolate the membrane fractions and would have served our purposes much better and
produced higher quality western-blots. This would have allowed us to assess AXL
expression in tumor tissue in a manner comparable to the experimental design seen in
Hutterer et al.45.
These shortfalls can be compensated for in a number of ways. Instead of obtaining
biopsied specimens and performing western blots, a better approach would be obtaining
sections of formalin-fixed paraffin-embedded (FFPE) tissue and performing
immunohistochemistry (IHC). This offers several major advantages to obtaining frozen
tissue, primarily in that it is collected whenever possible and is typically not in short
supply. Also, fixed tissues can be tested for molecular characteristics using IHC years
after its collection greatly extending the “shelf-life” of precious samples. Since a
complete collection of blood serum from all designated indicated time points were
difficult to obtain for a number of reasons, a viable option would be to supplement these
samples patient blood serum that is commercially available. Furthermore, the collection
of non-GBM blood samples including patients with lower grade brain tumors, non-GBM
tumors that are associated with sAXL like HCC98 would make us better equipped to
elucidate sAXL’s potential as a GBM biomarker.
Three of the four hypotheses were rejected: Circulating sAXL in patient blood
serum was not significantly decreased following surgical intervention, it was not
decreased in response to chemotherapy and radiation therapy, and pre-operative sAXL
did not significantly correlate with tumor volume. Despite this, it is important to consider
that this was performed on a small scale and with populations that weren’t matched
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ideally based on age, sex or other demographic characteristics. Due largely to time
constraints, multifaceted analysis of the MRI scans was not feasible and could have
answered several of the questions left unanswered here. In the future, the MRI scans will
be re-examined for further characteristics such as extent of necrosis, cell density of the
tumors, and infiltrating cells that would not have been readily detected using the T1weighted scans. Also, evaluating the relative expression and activity of the sheddase
ADAM 10/17 in the tumor tissue is a major component of sAXL release that could
explain the lack of correlation between tumor volume, membrane AXL expression, and
soluble AXL.
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CONCLUSIONS

In this study, we have demonstrated that there is potential for sAXL as a noninvasive biomarker for GBM but could not confirm it outright. Blood serum
concentrations of sAXL were found to be elevated in the group of GBM samples
collected prior to diagnosis and throughout treatment. Utilizing serum albumin
concentrations as a second characteristic to normalize sAXL against served to distinguish
pre-operative GBM blood serum from the healthy controls, albeit only modestly. Given
the highest sAXL levels seen were during treatment instead of prior to diagnosis, sAXL
alone would not likely function well as a predictive marker. Perhaps most promisingly, in
a subset of patients, grouped based on the abundance of sAXL relative to the control
population’s average, pre-operative sAXL levels showed a significant correlation with
AXL found in corresponding tumor tissue. This would suggest that sAXL is in fact being
released from tumor tissue and is subsequently detectable in the blood. While the natural
fluctuations of sAXL may mask this effect, designing a panel of similar proteins could
prove effective in predicting GBM where sAXL alone could not. Based on the evidence
presented here, we believe that repeating this study in a larger and modified fashion is
merited.
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